Citing a Neuro-QoL Measure
If you used a Neuro-QoL CAT, use the Gershon et al 2012 Quality of Life Research article. If you used a Neuro-QoL short form, reference Cella et al 2012 Neurology. If you used a pediatric Neuro-QoL measure, cite Lai et al 2012 from Neurorehabilitation and Neural Repair.
Measure Development & Research
Neuro-QoLTM instruments were developed through a collaborative, multi-site research initiative to construct psychometrically-sound and clinically-relevant health-related quality of life (HRQOL) measurement tools for individuals with neurological conditions or disorders such as stroke, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), epilepsy, and muscular dystrophy (MD). This initiative was sponsored by the National Institute for Neurological Disorders and Stroke. The HRQOL domains included in Neuro-QoL were identified through several sources, including an extensive literature review, an online Request for Information (RFI), two phases of in-depth expert interviews (n=44 and n=89, respectively), patient and caregiver focus groups (N=11 groups) and individual interviews with patients and proxies (N=63).
On the basis of this input, 17 HRQOL domains and sub-domains were chosen for adults and 11 for children, organized within adult and child domain frameworks. Items were selected for inclusion in each domain through a multi-step, iterative process to ensure item relevance, translatability, clarity, and comprehensive content coverage. The resulting item pools underwent calibration testing in both US general population and clinical samples using two-parameter logistic (2-PL) Item Response Theory (IRT) analyses to form the final item banks and scales. The scales and short forms (5-10 items each) from each bank were subsequently validated in adult and pediatric clinical samples. Details of the field testing, calibration, and validation studies can be found in the Neuro-QoL Technical Report. The resulting Neuro-QoL item banks and scales enable reliable assessment of multiple domains of functioning for adults and children with neurological conditions or disorders, including physical, mental, and social well-being.
Neuro-QoL measures were translated into Spanish and other languages. Translations result from a process of forward and back-translation, multiple expert reviews, harmonization across languages, and cognitive debriefing with a sample of native speakers of the target language (linguistic validation). A universal approach to translation ensures that, whenever possible, one language version is created for multiple countries instead of country-specific versions of the same language.
For further information on Neuro-QoL research and development, see the final report, which provides details on the methods for Neuro-QoL development. Information on Neuro-QoL instrument properties, psychometrics, scoring, and instrument statistics can be found in the user manual. Neuro-QoL publications are listed here, including an overall instrument development paper, one on item calibrations, and one on short form development.
Following the initial development and validation of Neuro-QoL measures, they were expanded for use in traumatic brain injury (TBI), military deployment–related traumatic brain injury (MDR-TBI), spinal cord injury (SCI), and Huntington’s disease (HD).
Exciting and novel research using Neuro-QoL measures continues to unfold, including a 2016 study by Meehan and colleagues that utilized Neuro-QoL measures (supplemented by a PROMIS® short form measure of Alcohol: Negative Consequences) to investigate whether sub-concussive blows during Division III college collision sports affect quality of life in later life. Results revealed that “negative consequences of alcohol use” was the only outcome positively associated with sub-concussive blows. Participants with a history of concussions, on the other hand, reported worse self-reported health (i.e., cognition, executive function, positive affect, anxiety, depression, negative consequences of alcohol use, sleep disturbance, emotional and behavioral dyscontrol, fatigue). The researchers concluded that while participation in collegiate level Division III collision sports, in itself, is not a risk factor for worse long-term neurobehavioral outcomes, athletes with a history of concussion might experience worse health outcomes in later life.
Another study by Morgan and colleagues utilized Neuro-QoL to investigate differences in self-reported cognition between people with lower limb loss and a normative US population sample. Findings suggest that persons who have lost a lower limb self-report greater cognitive concerns than the general population. The authors recommend including self-report measures such as Neuro-QoL in practice for use in customizing care plans and patient education efforts.
Katzan and colleagues (2018) used Neuro-QoL and PROMIS computer adaptive tests to evaluate symptoms and function following different types of cerebrovascular events. In a large (n=2,181) observational cohort study, they found that physical function, satisfaction with social roles, and executive function were most affected. Similar effects were seen in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Patients with transient ischemic attacks reported worse symptoms and function for many domains of health. Predictors of worse scores included female sex, younger age, lower income, and more recent stroke.
HDQLIFE is a set of self-report measures within Neuro-QoL that assesses the health-related quality of life (HRQOL) of adults with Huntington disease (HD). The HDQLIFE measures were developed through a collaborative, multi-site NIH-sponsored research project and is comprised of item banks and scales that evaluate symptoms and concerns important to those with HD. The HDQLIFE measures are intended for use in both clinical trials and clinical practice. The HDQLIFE measurement system consists of measures that cover 5 HD-specific domains, as well as 12 generic domains through the Neuro-QoL and PROMIS systems.